Ocular Therapeutix Appoints David Robinson as Global Chief Commercial Officer
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 21 2026
0mins
Ocular Therapeutix (OCUL) announced that David Robinson has agreed to join the Company as Global Chief Commercial Officer. Prior to joining Ocular, Robinson served as Chief Marketing Officer, Global Ophthalmology at Merck (MRK)
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on MRK
Wall Street analysts forecast MRK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MRK is 119.53 USD with a low forecast of 95.00 USD and a high forecast of 139.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
16 Analyst Rating
11 Buy
5 Hold
0 Sell
Moderate Buy
Current: 106.900
Low
95.00
Averages
119.53
High
139.00
Current: 106.900
Low
95.00
Averages
119.53
High
139.00
About MRK
Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eikon Therapeutics Files for U.S. IPO Valued Up to $908 Million
- IPO Filing: Eikon Therapeutics has filed for a U.S. IPO seeking a valuation of up to $908 million with approximately 17.6 million shares offered, reflecting its ambitions in cancer drug development.
- Funding Target: The company aims to raise about $273.5 million in net proceeds (nearly $315.4 million including underwriters' option), which will provide crucial funding for its ongoing research and development efforts.
- Leadership Background: Eikon is led by Roger Perlmutter, former president of Merck Research Laboratories, along with several other ex-Merck executives, highlighting its strong expertise and experience in the biotech sector.
- Clinical Trial Progress: Eikon's lead drug, EIK1001, is expected to release initial data from a global Phase 2/3 registrational trial for advanced malignant melanoma in H2 2026, which could significantly advance the company's position in oncology treatment.
Continue Reading
Moderna Stock Rises 58% in 2026, Signaling New Opportunities
- Stock Rebound: Moderna's stock has surged 58% in 2026, indicating a potential start of a sustained bull run after several years of stagnant revenue growth.
- Clinical Trial Progress: The intismeran autogene, in combination with Merck's Keytruda, demonstrated a 49% reduction in disease recurrence or death in advanced melanoma patients, highlighting its potential in cancer treatment.
- Product Portfolio Expansion: In addition to intismeran autogene, Moderna is conducting up to eight phase 2 or phase 3 clinical trials, and meaningful progress could significantly enhance the company's market competitiveness and product diversity.
- Long-Term Investment Value: Despite a substantial decline in stock price over the past three years, Moderna's strong performance in 2026 and future clinical and regulatory advancements make it a compelling consideration for long-term investors.
Continue Reading